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Abstract
Posterior vitreous detachment (PVD) is a
common phenomenon in the aging eye.
However, this may be complicated by persis-
tent symptomatic vitreomacular adhesions that
exert tractional forces on the macula (vitreo-
macular traction; VMT). VMT itself may be
associated with epiretinal membrane forma-
tion and the development of idiopathic
macular holes (IMH). Such patho-
logies may cause visual disturbances, includ-
ing metamorphopsia, photopsia, blurred
vision, and decreased visual acuity, which
impact an individual’s quality of life. Tech-
nologies such as optical coherence tomo-
graphy allow an increasingly more accurate
visualisation of the macular anatomy, includ-
ing quantification of macular hole character-
istics, and this facilitates treatment decision-
making. Pars plana vitrectomy remains the
primary treatment option for many patients
with VMT or IMH; for the latter, peeling of the
inner limiting membrane (ILM) of the retina
has shown improved outcomes when com-
pared with no ILM peeling. The development
of narrow-gauge transconjunctival vitrectomy
systems has improved the rate of visual
recovery following surgery. Ocriplasmin, by
degrading laminin and fibronectin at the
vitreoretinal interface, may allow induction of
PVD in a non-invasive manner. Indeed, clin-
ical studies have supported its use as an
alternative to surgery in certain patient popu-
lations. However, further research is still
needed with respect to greater understanding
of the pathophysiology underlying the
development of VMT and IMH.
Eye (2013) 27, S1–S21; doi:10.1038/eye.2013.212
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Normal vitreoretinal physiology
The vitreous gel is responsible for the
stabilisation of the eyeball; collagen fibres
(largely type II) run in an anterioposterior
direction through its centre, blending into the
anterior vitreous base, and inserting into the
posterior vitreous cortex (Figure 1).1–4 Spaces
between the collagen fibrils are maintained by
the protein opticin, and the fibril-associated
glycosaminoglycan chondroitin sulphate.3,5
These spaces are filled with water (which
constitutes 498% of the vitreous gel) and
hyaluronic acid.1,3,4,6 The vitreous gel is
therefore constructed to resist both tractional
and compressive forces.4 Recently, further
interest has been shown in a common feature of
normal vitreous known as the posterior
precortical vitreous pocket. This was first
described by Worst,7 and can appear on optical
coherence tomography (OCT) as boat-shaped
lacunae in the macular region, with a thin
posterior vitreous cortex that is thinnest at the
fovea.8 However, its exact physiological
function is unknown.
The interface between the vitreous gel and retina
(vitreoretinal interface; VRI) is a complex structure.9
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The more densely packed collagen fibrils of the posterior
vitreous cortex (which is 100–300mm in thickness) lie over the
macula and are superficially inserted into the internal
limiting membrane (ILM) of the retina.3,4,10 These are
attached by adhesion molecules such as laminin, fibronectin,
and heparan sulphate proteoglycans, which interact with
opticin in the vitreous gel.4,5,11 The vitreous gel itself is most
firmly attached to the retina at the vitreous base, optic disc,
and fovea, and along the major retinal blood vessels.9 In
particular, the attachment at the vitreous base is very strong
and is generally fixed unless severe blunt trauma occurs.
Indeed, the attachment is so tenacious that under such
circumstances, the pars plana epithelium also detaches with
the vitreous base. Conversely, it is possible to separate
attachments at the optic disc, fovea, and retinal blood vessels
surgically in most cases albeit with difficulty in younger
patients.
Normal aging is accompanied by a number of
physiological changes in the vitreous gel. After the age of
40, it undergoes progressive liquefaction (synchisis), with
fluid escaping through defects in the posterior vitreous
cortex, eg, those at the optic disc or prepapillary hole.3,4
This results in the development of fluid-filled pockets,
which generally begin in front of the macula, enlarging the
premacular vitreous pocket but also in the central vitreous
cavity.6 Typically by the age of 80 years, around 50% of the
vitreous gel has been liquefied.4,6 This corresponds with a
simultaneous decrease in gel volume and a lateral
aggregation of the collagen fibrils.3 Over time, the fluid-
filled pockets coalesce and enlarge, and a gradual
destruction of the collagen-hyaluronate network occurs,
resulting in a weakened adhesion between the vitreous and
retina.2,4 This leads to the eventual development of a
shallow localised separation of the vitreous gel from the
perifoveal area of the retina, which progresses over time
(Figure 2).2,12 Finally, total collapse of the collagen fibrils
(synaeresis) leads to complete detachment of the posterior
vitreous from the retina, and the vitreous gel now occupies
an anterior position in the vitreous cavity.3,6
This process occurs over several months or years.2 In
many cases, the process of posterior vitreous detachment
(PVD) is asymptomatic, until vitreous separation from
the optic disc occurs.2 Symptoms of complete (acute)
PVD include light flashes and floaters. Light flashes are
caused by vitreous traction on the peripheral retina, while
floaters may be due to blood, condensations of vitreous
collagen, or glial tissue torn from the optic nerve.13
Studies in healthy adults with otherwise normal eyes
have shown that focal perifoveal PVD occurs in around
50% at ages 30–39 years, whereas complete PVD is
observed in 50% or more of individuals aged 70 years or
older.12,14–16 PVD is significantly more common in
postmenopausal women than men; this is thought to be due
to the effects of decreased oestrogen on connective tissues
such as those within the vitreous gel.6,17 The presence of
myopia is also associated with a three- to fourfold increased
risk of PVD compared with absence of myopia.17
Pathophysiology of vitreomacular traction and macular
hole
Vitreomacular traction
Normal age-related PVD may be complicated by
persistent vitreomacular adhesions (VMA) between the
vitreous cortex and the macular area following
synaeresis.2,9,18 Such adhesions can be focal or broad,
Figure 1 The orientation of collagen fibrils within the vitreous
gel (adapted from Le Goff and Bishop4). Redrawn with
permission from P Bishop, The University of Manchester.
Figure 2 Stages of posterior vitreous detachment (PVD) during
healthy aging (adapted from Johnson;2 Uchino et al12). Stage 1,
perifoveal vitreous detachment with residual vitreofoveal
adhesion; Stage 2, perifoveal vitreous detachment with persistent
attachment to the optic disc but without vitreofoveal adhesion;
Stage 3, near-complete PVD with only vitreopapillary adhesion
remaining; Stage 4, complete PVD.
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encompassing the foveola only, or a wider region of the
macular area and the optic disc.19,20 Simple
(asymptomatic) VMA is not associated with structural
distortion of the macular architecture (Figure 3).
However, such adhesions may exert tractional forces
on the macula (vitreomacular traction; VMT), increased
during ocular saccades, causing retinal distortion and
disruption.18 Increasing width of the VMA is
associated with a decreased tractional force and
therefore reduced foveal deformation. For example, the
smallest adhesions at the fovea may result in focal
inner retinal cavitation (foveal cyst) (Figure 4), while
larger vitreoretinal adhesions (Z1500 mm) can lead to
more generalised foveal profile flattening (ie, a loss of
foveal depression) and detachment.20–22 VMA and
VMT may be differentiated by clinical symptoms
(chiefly, visual loss, blurred vision, and
metamorphopsia) and with OCT.2 However, some
cases of VMT may not demonstrate obvious deleterious
effects on vision.
In many VMT cases, an epiretinal membrane (ERM;
10–20mm in thickness) develops during the early
perifoveal stages of PVD (Figure 5).2,23 Histologically, two
types of ERM can be observed; a simple or type 2 ERM
growing directly on the ILM composed of a monolayer of
retinal glial cells producing type IV collagen—retinal
pigment epithelial (RPE), fibroblastic, and inflammatory
cells are absent; and a more complex or type 1 ERM
sometimes containing cells such as fibrous astrocytes,
myofibroblasts, fibrocytes, macrophages, and RPE cells, in
addition to glial cells.23–27 Multilayered sheets of cells can
be seen and are separated from the ILM by a layer of
native vitreous (type II) collagen remaining after
incomplete PVD (Figure 6).23,26,27 Growth factors within
the VRI may contribute to fibrocellular proliferation.27 The
native collagen is thought to facilitate the proliferation of
ERM by acting as a scaffold.23,28 The corresponding side of
the split and detached vitreous cortex, forming the outer
surface of the ‘cone’, also acts as a scaffold and thus
cellular proliferation occurs along both sides of this
aberrant VRI and is thought to contribute to the tenacity of
VMA in VMT (Figure 7).20,23
The presence and type of ERM also contributes to the
morphological alterations observed at the VRI. Simple
(non-contractile) ERM is associated with retinal surface
wrinkling ‘cellophane’ maculopathy (an irregular
Figure 3 Central foveal vitreomacular adhesion without traction. Left, fundus photography; right, optical coherence tomography
(OCT); green line corresponds with level of OCT image. Reproduced with permission from DH Steel.
Figure 4 Vitreomacular traction with retinal cavitation. Left, fundus photography; right, optical coherence tomography (OCT); green
line corresponds with level of OCT image. Reproduced with permission from DH Steel.
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glistening) observed on light reflex with no distortion of
the inner retina.23,29 However, the contraction of
myofibroblasts within the more complex type of ERM
has been proposed to exert a tangential traction at the
VRI, which can result in retinal puckering, thickening,
folding, or detachment, together with vascular
distortion.27,29–31 Contraction of complex ERM can
therefore exert profound effects on vision29 and
significantly increase the effect of any VMA. VMT
and any associated ERM can also be associated with
changes in the retinal vasculature.9 As the retina is pulled
apart, there is a reduction in interstitial fluid pressure,
with subsequent fluid influx from the retinal vasculature
(ie, leakage of blood) and cells, leading to macular
oedema.18
Although outside the scope of this review, a meta-
analysis has estimated that VMA (including VMT) is
found in a reported 23% of eyes in patients with
exudative (wet) age-related macular degeneration
(AMD) and often the area of adherence corresponds to
the area of choroidal neovascularisation.32 The nature of
this relationship is unclear and its aetiological
significance uncertain. It may represent a secondary
phenomenon although still exacerbate disease course
and response to treatment.
Similarly, the relationship between VMT and diabetic
macular oedema (DMO) has also been examined. In the
recent meta-analysis conducted by Jackson et al,32 it was
estimated that VMT (and ERM with traction) was present
in 29% of DMO cases scheduled for surgery. Individual
studies have estimated the prevalence of any type of
epimacular traction including both epiretinal membrane,
vitreoschisis with a splitting of the vitreous cortex termed
vitreoschisis, and classic VMT occuring overall in 24–32%
of eyes with DMO.33,34 The presence of asymptomatic
VMA has been reported to increase the risk of diffuse
DMO by more than threefold when compared with
diabetic patients demonstrating complete PVD or
Figure 5 Vitreomacular traction with epiretinal membrane. Left, fundus photography; right, optical coherence tomography (OCT);
green line corresponds with level of OCT image. Reproduced with permission from DH Steel.
Figure 6 Fibrous epiretinal membrane visualised using trans-
mission electron microscopy. Collagen fibrils (between the
arrowheads) situated between the inner limiting membrane of
the retina and a layer of fibrocytes (shown by the arrow). The
layer of collagen fibrils isB10 nm in thickness. Reproduced with
permission from R Spaide, Vitreous-Retina-Macula Consultants
of New York, New York, USA.
Figure 7 Complex epiretinal membrane formation (adapted
from Chang et al23). VRI, vitreoretinal interface. Reproduced
with permission from R Spaide, Vitreous-Retina-Macula
Consultants of New York, New York, USA.
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complete vitreoretinal attachment.35 Asymptomatic
VMA is also associated with a significantly reduced
likelihood of spontaneous DMO resolution relative to
patients whose eyes demonstrate complete PVD.36 Type 2
ERMs are common with VMT in patients with tractional
DMO.37
Macular hole
Idiopathic macular holes (IMHs) are round full-thickness
vertical retinal defects in the foveal neurosensory
retina.31,38 Gass hypothesised that IMHs begin with
tangential traction of the prefoveal vitreous cortex, which
results in a foveal dehiscence that progresses from foveolar
detachment to a full-thickness IMH.39,40 However, more
recent research (using ultrasound and OCT) has elucidated
that IMHs are initiated during perifoveal PVD as a
consequence of anteroposterior and dynamic VMT.41–43
The anterior tractional forces acting at the foveola
firstly produce an intrafoveal split, which evolves into a
foveal pseudocyst (Figure 8).21,44,45 The pseudocyst may
then become extended, disrupting and separating the
outer retinal layer while raising the inner retinal layer
(Figure 9).38,44,45 Degeneration of the retinal tissue
secondary to these tractional forces at the foveola may
facilitate this process.
Dehiscence of the foveal cyst creates a full-thickness
defect, including the inner/outer segment (IS/OS)
junction of the photoreceptor layer.38,44,46 Complete
detachment of the cyst roof can be observed by the
appearance of an operculum within the vitreous gel,
which consists of glial tissue and hyperplastic Mu¨ller
cells from the inner retinal surface, as well as
components of the outer retina including cone cells in up
to 65% of cases (Figure 10).38,43,47
Before the creation of a full-thickness retinal defect, the
evolving macular hole corresponds to Gass’s stage 1.
A stage 2 hole is a full-thickness defect less than 400mm
in width and a stage 3 hole greater than 400 mm in width.
Stage 4 refers to the situation when the vitreous separates
over the entire posterior retina, including the optic disc,
with a Weiss ring observed fundoscopically.38,40 In total,
B55% of patients presenting with IMH exhibit VMT to
the edges of the IMH, with 67% of stage 2 holes having
VMT (Figure 11), but very few with stage 3 IMH having
persistent VMT.38 Conversely, some stage 4 holes can be
less than 400mm in size.
A small early IMH has the capacity to repair itself after
complete VRI separation via proliferation of retinal glial
cells.43 Paradoxically, if this repair mechanism fails, glial
cells migrating to the edge of the hole can progressively
contract, resulting in its enlargement. The edge of the IMH
subsequently becomes progressively elevated by a cuff of
subretinal fluid that may be accompanied by thickening of
the neurosensory retinal tissue (Figure 12).48,49
Figure 8 Vitreomacular traction with pseudocyst. Left, fundus photography; right, optical coherence tomography (OCT); green line
corresponds with level of OCT image. Reproduced with permission from DH Steel.
Figure 9 Vitreomacular traction with inner retinal cystic
change and outer retinal detachment. Reproduced with permis-
sion from DH Steel.
Review of vitreomacular traction and idiopathic macular hole
DHW Steel and AJ Lotery
S5
Eye
Lamellar macular holes are formed by the same
process as full-thickness IMH with the exception
that the photoreceptor layer remains intact.45,50,51
On OCT, an irregular defect in the inner retina
is seen, with an intact outer retina and a near-normal
perifoveal retinal thickness (Figure 13a).52 Macular
pseudoholes (Figure 13b) are fundoscopically apparent
holes ERM that is associated with a thickened but
intact neurosensory retina and are often associated
with good vision. They are characterised by a steep
foveal pit of a small diameter, with thickened foveal
edges.52 However, a mixed appearance may also be
seen (Figure 13c).
A variety of traumatic events including blunt trauma,
phototoxicity, spontaneously resolved VMT/IMH and
other unrecognised causes can cause localised outer
retinal defects, which appear as tiny (50 100mm)
apparent foveal microholes.53 The inner retina remains
intact and the condition is non-progressive, occurring in
patients of all ages. The visual acuity is often good
although the patient may be aware of a central scotoma.53
Figure 10 Idiopathic macular hole with operculum. Left, fundus photography; right, optical coherence tomography (OCT); green line
corresponds with level of OCT image. Reproduced with permission from DH Steel.
Figure 11 Small idiopathic macular hole with vitreomacular attachment. Left, fundus photography; right, optical coherence
tomography (OCT); Green line corresponds with level of OCT image. Reproduced with permission from DH Steel.
Figure 12 Macular hole with elevated cuff. H, height; MLD,
minimum linear diameter; BD, base diameter. Macular hole
index (MHI)¼height (H)/base diameter (BD). Reproduced with
permission from DH Steel.
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Risk factors and epidemiology
Few studies have specifically investigated the epidemiology
of idiopathic VMT, due to its overlap with many other
ocular disorders and abnormalities. However, it has been
estimated that the prevalence of VMT in isolation from IMH
is B22.5 per 100 000 of the general population, while the
incidence is estimated as 0.6/100 000 per year.54 In
observational and interventional studies, the mean age of
patients diagnosed with VMT is around 65–75 years (range
B48–83 years), with a predominance of females.2,19,20,23,26
IMH predominantly occurs in individuals aged 465
years.9,42,55,56 The prevalence of IMH has been estimated
at around 0.1–0.8% of adults aged 440 years,57–61 while
the age-adjusted incidence has been reported as 7.8 per
100 000 of the general population per year.56
Approximately two-thirds of patients are women and
the condition is unilateral in around 80% of cases.42,55,56
A number of factors have been suggested to increase the
risk of IMH development, such as elevated plasma
fibrinogen,62 while in women, use of oestrogen-replacement
therapy is associated with a reduced risk of IMH. In
individuals with severe myopia ( 14 to  32 dioptres), the
prevalence of IMH has been reported to be as high as 6%.63
Notably, the risk of IMH development in fellow eyes
without manifest vitreous separation has been estimated at
around 7–12% after 5 years and 17% at 10 years.55,64
Assessment and diagnosis
Symptoms at presentation
The cardinal symptoms of VMT are related to the
structural macular changes associated with the condition
and include decreased visual acuity (VA),
metamorphopsia, micropsia (a diminution of objects
within the visual field), and rarely photopsia (luminous
rays or flashes).2,18,31 However, even in patients with
visible VMT, symptoms may be absent. The impact of
age-related eye disease (including IMH) on quality of life
is substantial. Impairments in physical activity, engaging
in close activities, and decreased social interaction, as
well as emotional effects have been reported.65 Vision-
dependent activities such as reading small print, reading
road signs, and driving at night can all be affected.65,66
Most stage 1 and many stage 2 IMHs are asymptomatic,
especially if the other eye is normal and the non-dominant
eye affected.67 However, late-stage IMHs are associated
with significantly reduced VA, metamorphopsia, and loss
of central vision with a central scotoma, usually resulting
in severe visual impairment.9,55,58 VA is inversely
correlated with the size of the IMH.55
Diagnostic tools
As a first step in patients with suspected VMT/IMH, a
thorough history needs to be taken, which should
include the duration and type of symptoms,
ophthalmological history (glaucoma or other disorders,
traumatic injuries, surgery, or other treatments), and the
use of medications that are potentially related to the
development of macular cysts (eg, systemic niacin,
topical prostaglandin analogues).68,69
There are a number of technologies that allow
visualisation of the vitreous and retina that can aid the
identification and characterisation of VMT and/or IMH;
these allow differentiation from other fundoscopically
similar disorders such as central serous retinopathy,
subfoveolar drusen, and solar maculopathy.68,69
Visualisation of the fundus should include the peripheral
retina to exclude pathology such as retinal tears and
vascular lesions.70 Fundus photography and in particular
red-free or blue-reflectance imaging can highlight the
presence of ERM associated with vascular distortion, and
also ERM with macular pseudohole.2 Funduscopically,
Figure 13 Lamellar macular hole and macular pseudohole.
(a) Lamellar macular hole. (b) Macular pseudohole with epiretinal
membrane. (c) Macular pseudohole with lamellar hole formation.
Left, fundus photography; right, optical coherence tomography
(OCT); green line corresponds with level of OCT image.
Reproduced with permission from DH Steel.
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IMH may exhibit some or all of the following: fine,
drusen-like yellow deposits in the base of the hole, a
surrounding cuff of subretinal fluid, a distinct circular
margin around the hole, and an operculum (viewed as a
small round opacity suspended within the vitreous gel
over the fovea).70 A complete PVD is characterised by a
mobile prepapillary Weiss ring, which is associated with
a faintly visible posterior hyaloid membrane and an
optically empty subhyaloid space. However, fundus
examination does not identify localised shallow (ie, early,
asymptomatic) PVD without posterior vitreous cortex
thickening and cannot detect translucent adhesions of the
vitreous gel at the macula.
Dynamic B-scan ultrasound permits visualisation of
the early stages of PVD and also the presence of an
operculum.2 It can facilitate differentiation of IMH from
idiopathic macular pucker caused by ERM (which
characteristically exhibits a complete PVD and Weiss
ring).71 However, it provides relatively low-resolution
images relative to OCT.
OCT remains the most accurate method for visualising
the VRI and identifying VMT and/or IMH.31,72 Within
the last few years, spectral domain OCT (SD-OCT) has
become more widely available, providing even higher-
resolution images (axial resolutions of a little as 5 mm)
and reducing artefacts produced by the moving parts of
conventional OCT.73 This improved technology can
therefore provide detailed visualisation of VMT and/or
ERM (Figure 5), retinal distortion, and macular
detachment.19,20,22 This includes the accurate
quantification of vitreous adhesions (horizontal and
vertical) and foveal cavitation in patients with VMT.19
SD-OCT may also discriminate between pseudocysts
secondary to VMT and cystoid macular oedema.20,23
SD-OCT has allowed a more accurate staging of IMH
(Figure 9).38 Visualisation of foveal anatomy (including
intraretinal cavitation) can identify changes indicating
impending macular holes, potentially allowing for early
intervention.19,74 SD-OCT can also be used to accurately
measure various characteristics of macular holes
including base width, minimum linear diameter, height,
and a variety of macular hole ratios including the
macular hole index (Figure 12),75–78 as well as
distinguishing between IMH, macular pseudohole, or
lamellar macular hole.79 An important clinical
consideration is the choice of scanning protocol used
especially when assessing macular holes—vertical and
horizontal scans with a wide spacing between lines could
miss areas of focal vitreous attachment or full-thickness
retinal defects, or underestimate true IMH size. Using the
lowest line spacing protocol available or a radial pattern
scan through the fovea can reduce this risk.
In both VMT and IMH, SD-OCT permits accurate
follow-up and monitoring of patients undergoing
surgical or other procedures, or over a period of
observation.20,31,80 More accurate prognosis for vision
recovery may be possible by assessing the structural
integrity of the photoreceptors at the site of the IS/OS
junction defect, the integrity of the external limiting
membrane (ELM), and outer diameter of the foveal
defect before and following intervention.46,79,80 Studies
have also indicated that preoperative base diameter,
inner opening diameter, and minimum linear diameter
can predict the outcome of vitrectomy for IMH.81
Fluorescein angiography may be employed in some
cases where it is suspected that other pathologies may be
present, such as choroidal neovascularisation, parafoveal
telangiectasia, or previous and clinically occult retinal
vein occlusion.
Treatment options
Observation
In a small number of cases, VMT resolves spontaneously
without intervention (reported incidences are 10–11%).82,83
The tenacity of the adhesion between the vitreous gel and
macula determines the likelihood of spontaneous PVD.2
One study utilising SD-OCT re-examined patients’ VMT at a
period of 4 12 months after the first assessment; persistent
VMT was associated with the presence or development of
ERM and also the largest horizontal VMA.84 However,
resolution is hard to predict, so observation is currently
recommended as standard of care for at least 3 months
before initiating any treatment in order to avoid
unnecessary surgery.
In the Eye Disease Case–Control Study, after 3 years of
follow-up in patients with pre-existing IMH, 21.7%
demonstrated an enlargement; this rose to 37.1% after 6
years.55 Spontaneous regression or resolution of IMH
was observed in 9% of patients after 6 years of follow-
up.55 Over a period of at least 1 year, deterioration in VA
of two Snellen lines or more has been reported for 30% of
patients with stage 1, 68% with stage 2, 29% with stage 3,
and 13% with stage 4 IMH.85 However, central retinal
detachment secondary to IMH appears to be limited to
patients with high myopia.86
Generally, most macular pseudoholes and lamellar
macular holes tend not to progress anatomically over a
period of several years and are usually not associated
with significant decreases in VA.87,88 However, some
macular pseudoholes may be associated with decreased
VA in some cases (eg, with lamellar cleavage of the
edges), and in such instances, surgery may be
performed—vitrectomy with ERM and ILM peeling.89
Maintenance of VA in eyes with lamellar macular holes is
associated with preservation of the ELM.90 As with
macular pseudoholes, vitrectomy with ILM peeling may
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be performed in patients with impaired VA or
symptomatic distortion—optimal results are obtained
when the IS/OS junction and ELM are intact.91,92
Vitrectomy
Technology The primary aim of any intervention in
patients with VMT and/or IMH is to release the residual
VMA, facilitating a restoration of normal central retinal
architecture, and with closure of a macular hole if
present. Vitrectomy has been the only method available
until now to achieve this.
Closed pars plana vitrectomy (PPV) (Figure 14) was
first described by Machemer in 1971.93 Subsequently, the
technique has undergone several advancements with
narrow-gauge transconjunctival sutureless vitrectomy
(TSV) now being routinely carried out. 20-, 23-, 25-, and
27-gauge systems are all available and have relative
advantages and disadvantages (Table 1). Enhancements
in illumination and wide-field viewing systems have
optimised the surgeon’s view of the retina. In addition,
cannulated and valved entry systems with high-speed
efficient cutters have minimised retinal traction and
trauma, reducing perioperative unintentional retinal
break formation and postoperative retinal detachment.
Kelly and Wendel94 first described vitrectomy to close
macular holes in 1991 and since then a number of
refinements and variations have been described. During
vitrectomy, separation of the posterior hyaloid face from
the retina is carried out by aspiration if not already
present and the core and peripheral vitreous removed.
Peeling of the ILM has been shown to increase MH
closure rates. It is thought to work by: (1) removing
residual adherent vitreous cortex remnants on the ILM
surface; (2) removing associated fibrocellular collections;
(3) removing the rigid and less compliant ILM (relative to
the retina itself); and (4) causing a retinal glial cell
proliferation that may paradoxically help macular hole
contraction and repair.43,95 Peeling is generally carried
out using a pinch-peel technique with fine-tipped
forceps. Various aids to initiate peeling such as the Tano
diamond dusted scraper are also used. The ILM is
usually peeled to a radius of approximately one disc
diameter around the hole.
A variety of dyes including indocyanine green (ICG),
Trypan blue, and Brilliant Blue G can be used to aid
visualisation of the ILM.71,72,96–98 They demonstrate
varying degrees of ILM specificity and are sometimesFigure 14 Pars plana vitrectomy.
Table 1 Advantages and disadvantages of conventional sutured 20-gauge pars plana vitrectomy vs narrow-gauge transconjunctival
systems with cannulated sclerotomies101,135,136,138,163–167
Advantages Disadvantages
20-Gauge More rigid instruments.
Availability of angulated scissors.
Greater potential illumination.
Higher achievable flow rates.
Less prone to clogging with dense material.
Sutures needed to close conjunctiva and sclerostomies
with postoperative surface discomfort and irritation.
Higher rate of sclerostomy-related retinal breaks.
Requirement for plugs to close sclerostomies when
instruments removed from eye.
Reduced globe stability with higher potential for surge.
Narrow-
gauge
Less conjunctival disruption and faster surface recovery with
less postoperative discomfort.
Quick entry and exit from the eye.
Less potential for entry site trauma and lower incidence of
entry site-associated retinal breaks.
Lower flow rates with narrower field flow effects and less
retinal traction.
Smaller cutter port size with more precise end cutting ability.
Valved sclerostomies eliminate unwanted sclerostomy
leakage.
Postoperative hypotony with sclerostomy leak in some
cases.
Change in technique needed to use instruments
Lower achievable flow rates.
Occasional requirement to open conjunctiva and enlarge
sclerostomy to introduce larger instruments.
Lower infusion flow rates with higher resistance.
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used sequentially to peel ERM if present and then ILM.
Increasingly, agents designed to settle onto the retina in
fluid are used to avoid the need for fluid-air exchange.
Dyes are left on the retinal surface for the minimal time
to allow staining (typically less than 1 min) before being
washed out to reduce the possibility of toxic effects.
In particular, there has been much debate about the risks
of toxicity with ICG.
Following completion of vitrectomy and ILM peeling
and careful checking of the peripheral retina for retinal
tears, an air-fluid exchange is carried out, with
subsequent gas exchange.97,98 Gas is used to facilitate
hole closure by two key mechanisms. First, the surface
(interfacial) tension of the gas across the hole prevents
trans-hole fluid flow from the vitreous cavity and also
reduces trans-retinal uveal-scleral outflow with reduced
retinal oedema. The gas interface also acts as a surface to
allow glial cell migration to bridge the gap between the
retinal edges.43,99 A variety of gases have been used to
achieve the above aims with a gradual change in practice
from most surgeons using longer-acting gases such as
perfluoropropane (C3F8) to an increasing use of shorter-
acting gases such as sulphur hexafluoride (SF6) or even
air.20,76,100,101 Silicone oil, both light and heavy, have been
used by some surgeons following failure to close IMH at
a first procedure.77 Once the gas has been absorbed (or oil
removed), the aqueous humour gradually fills the
vitreous chamber. Vitrectomy with gas in the age group
affected by IMH commonly results in cataract formation
and phacoemulsification is commonly combined with
vitrectomy to speed visual recovery.
Adopting a face-down posture after completion of PPV
has been recommended conventionally, but it has been
increasingly realised that this is not always necessary,
particularly with smaller holes.77,102 Gas can still bridge
the defect of a macular hole without face-down
positioning as long as the patient does not lie supine for
the whole duration.
With vitrectomy for VMT, again the main surgical aim is
to remove the aberrantly attached posterior hyaloid face.
ERM as described is a common accompaniment of VMT
and ERM and/or ILM peeling is commonly carried out as
well to remove all associated traction. Gas tamponade is
not routinely used unless it is needed to address peripheral
retinal pathology or to assist wound closure.
Clinical outcomes: VMT The majority of published
studies reporting results of PPV specifically for VMT
consist of small cohort studies. However, these all
indicate a high success rate. In an early report regarding
a series of 26 eyes, 15 demonstrated improvement in VA
of at least 2 Snellen lines (75%), with 8 achieving 20/50
VA or better.103 Similarly, in another series of 18 cases of
patients undergoing PPV and ERM peeling, there was VA
improvement in 72% of the eyes, with six achieving
20/40 VA or better.104 Among a different series of
29 eyes, following PPV VA was improved by Z2 lines
in 21.105 Preoperative VA of 0.25 or better predicted a
greater improvement in VA following surgery (0.42 vs
0.65 lines; P¼ 0.006). Similarly, in a larger series of 50
eyes, achievement of postoperative VA of 20/50 or better
was demonstrated only in eyes with preoperative VA
Z20/100 (66%).106 In a retrospective review of 20 eyes
with VMT that had undergone PPV with ERM peeling,
mean VA improved from 20/122 before surgery, to 20/68
following the procedure (P¼ 0.005).107
It is unclear if there is an additional benefit from ILM
peeling in addition to removal of the VMT and ERM, but
it is commonly practiced to ensure complete removal of
surface traction. In a single study involving 30 eyes with
VMT (VA o20/32) undergoing PPV with ERM removal
and ILM peeling, although retinal surface folds resolved
within 1 month after the procedure, recovery of IS/OS
retinal layer integrity was only achieved after 1 year.
However, VA improved progressively during the 2-year
follow-up period.108
Improvement in VA following PPV for VMT is also
correlated with the duration of symptoms, stage of VMT
(stage 1, focal vitreofoveal hyaloidal attachment with
perifoveal seperation; stage 2, vitreomacular and
papillomacular attachment; or stage 3, broad vitreofoveal
attachment) and preoperative central macular
thickness.109 Mean VA improvement was significantly
greater in patients with stage 1 VMT (2.82±1.47 lines) vs
stage 2 VMT (0.83±1.17 lines) or stage 3 VMT (1.29±0.49
lines) (P¼ 0.036 for trend).
Clinical outcomes: IMH Success rates in terms of closure
for IMH with vitrectomy are generally high (reported
85–100%);77,100,110 success rates of TSV and conventional
20-gauge PPV appear equivalent.110 However, a number of
IMH characteristics are thought to impact on successful
closure following PPV. These include a smaller base
diameter, smaller inner opening size, and shorter
minimum linear dimension.77,81 Visual success is also
correlated with base diameter, inner opening size, and
minimum linear dimension. In a recent analysis from a
multicentre database study in the UK, a total of 1078 eyes
from 1045 patients underwent PPV for IMH (94% also had
ILM peeling).111 At 12 weeks after surgery, 119 of 476
evaluable eyes (48.6%) had achieved success (defined as
Z0.3 logMAR units improvement (equivalent to 2 Snellen
lines)); this proportion increased to 58.3% at 52 weeks,
while 8% had deteriorated by 40.30 logMAR units.
A number of surgical aspects have been studied to
assess their effect on success rates. Several randomised
studies have been carried out on the efficacy of ILM
peeling added to surgery. In the FILM study at 1 month
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after the procedure, closure of the IMH was complete in
84% of the patients undergoing ILM peeling compared
with 48% who did not undergo ILM peeling (Po0.001).97
However, there were no differences in IMH closure
between the groups at 3 (92 vs 83%) and 6 months (94 vs
89%), reflecting the fact that patients with persistently
open holes underwent repeat surgery. Indeed at 3–6
months after surgery, there was no significant difference
between the groups for distance or near VA, or contrast
sensitivity. A total of 31 patients (48%) who did not
undergo ILM peeling required further surgery, of which
25 (38%) required ILM peeling during the follow-up
period. Reopening of IMH was reported for one eye in
the no ILM peeling group and none in the ILM peeling
group. A recent Cochrane review also concluded that
ILM peeling compared with no peeling increases the
chance for an IMH to close with a single surgical
procedure and reduces the chances of patients requiring
additional surgery without unwanted side effects.112
The authors added that as ILM peeling is likely to be
cost-effective, it may be considered the best available
option for individuals with IMH.
There is controversy, however, as to whether all sizes
of macular holes require ILM peeling. In a study by
Tadayoni et al,113 the authors proposed that ILM peeling
offers no additional benefit to PPV with removal of any
ERM when applied to eyes with IMH of o400 mm in
diameter. Closure rates in these smaller holes were 100%
for ILM peeling and 100% without ILM. In contrast, ILM
peeling for IMH Z400 mm resulted in successful closure
in all holes, compared with 73.3% of holes without ILM
peeling (P¼ 0.015). A retrospective study by the same
group showed that retinal sensitivity was significantly
reduced when comparing ILM peeling with no ILM
peeling; microscotomas were also significantly more
common in the ILM peeling group.114 In general, there
are also some concerns about possible adverse effects of
ILM peeling.115
There has been much debate regarding the effect of
various dyes used to facilitate ILM peeling (especially
ICG) and their effect on vision in particular. The results of
individual studies have been inconsistent; however, a
meta-analysis of pooled data from clinical trials has
assessed the use of ICG in patients undergoing PPV and
ILM peeling for IMH.96 There was no difference in IMH
closure rates between ICG and no stain or between ICG
and other dyes. The rates of VA gain Z20/40 were
comparable for eyes receiving ICG vs no dye at 1 year
(odds ratio (OR): 0.82; 95% confidence interval (CI):
0.49 1.35; P¼ 0.435), but were lower for ICG vs other
dyes (OR: 0.65; 95% CI: 0.43–0.97; P¼ 0.033). There was
no difference for ICG vs no dye or ICG vs other dyes for
rates of VA improvement Z2 Snellen lines. There is some
evidence of toxicity associated with dyes although again
results are difficult to interpret. In one study comparing
triamcinolone with Infracyanine Green in patients
undergoing PPV for IMH with ILM peeling, the latter
was associated with deleterious effects on the
photoreceptor cells.116
Numerous studies have reported the use of different
types of tamponade following PPV for IMH. Initially,
long-acting gases were always used but increasingly
shorter-acting ones and air are used: and increasingly
with gases the role of postoperative face-down posturing
and its duration has been questioned. In a study of 156
eyes from 151 patients, PPV was performed with ILM
peeling and either SF6 or air tamponade with
postoperative face-down posturing.117 Equivalent hole
closure rates were achieved (490% in both groups). A
different study reported closure rates of 55% at 24 h and
76% at 48 h following surgery with room air tamponade
and face-down positioning.118 In a separate cohort study,
SF6 was compared with perfluoroethane (C2F6) in
patients who did not assume a face-down posture after
surgery.119 IMH closure was achieved in 485% of
patients in both groups. At 6 months after the procedure,
mean VA improved from 0.78 logMAR to 0.38 logMAR in
the SF6 group and from 0.81 logMAR to 0.44 logMAR in
the C2F6 group. However, SF6 was absorbed more
rapidly than C2F6, having completely disappeared at 2
weeks following surgery. In another study, SF6 was
compared with C3F8 after PPV for IMH in 69 eyes.120
IMH closure rate was 90% with SF6 and 91% with C3F8.
At 6 months after surgery, mean VA significantly had
improved in both groups (SF6, 0.32 logMAR, P¼ 0.045 vs
baseline; C3F8, 0.52 logMAR, Po0.001 vs baseline).
In patients with persistent IMH following initial PPV
with ILM peeling and gas tamponade, the use of heavy
silicone oil has been associated with high success rates
for hole closure (92%).121 However, although when
compared with C3F8 tamponade for primary IMH
surgery, closure rates with silicone oil were comparable
(480%) in both groups, VA improvement to 20/70 or
better was achieved in fewer patients receiving silicone
oil than C3F8 (17.3 vs 73%).122 A separate study
comparing these types of tamponade reported IMH
closure rates of 65% for silicone oil and 91% with C3F8
(P¼ 0.022).123 A higher percentage of patients in the
silicone oil group also required a second procedure
compared with the C3F8 group (35 vs 4%; P¼ 0.006). In
addition, final median VA was superior for C3F8 (20/50)
vs silicone oil (20/70; P¼ 0.047).
A recent Cochrane Review analyzed three randomised
controlled trials directly comparing face-down posturing
following macular hole surgery with no face-down
posturing.124 For macular holes r400 mm, it was
concluded that there was no significant effect of
face-down posturing on successful hole closure.
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However, two of the studies found that there was a
significant benefit of face-down posturing on successful
IMH closure when the diameter was 4400 mm. A more
recent retrospective review of 208 eyes undergoing PPV
with ILM peeling followed by C3F8 tamponade reported
that in the absence of face-down positioning IMH closure
was achieved in 81% of eyes, accompanied by an
improvement in mean VA from 20/200 to 20/40.102
Another study obtained an IMH closure rate of 84%
following vitrectomy with phacoemulsification
(phacovitrectomy) and intraocular lens implantation
followed by SF6 tamponade, without face-down
positioning.77
Combined phacovitrectomy has been compared with
sequential vitrectomy and phacoemulsification (during
the first year following vitrectomy) in 120 eyes with IMH
and pre-existing cataract.125 Best-corrected VA improved
significantly at 6 months after phacovitrectomy, with no
significant further improvement after this time. However,
in the sequential procedure group, VA was only
improved at the 1-year follow-up. IMH closure at
1 month after one surgical procedure was 100% in the
phacovitrectomy and 96% in the sequential vitrectomy
and phacoemulsification group. There is no clear
evidence that combined phacovitrectomy affects the
long-term results of PPV for IMH but visual recovery
is quicker.
There is little literature regarding changes in quality of
life following vitrectomy for IMH. However, in two
studies involving a total of 101 patients, at 1 year
following PPV statistically significant improvements in
general vision, peripheral vision, close (near) and
distance activities, social functioning, mental health and
dependency were reported.66,126
Safety and complications Vitrectomy can be incomplete,
leaving remnants of vitreous cortex on the ILM, with the
consequences of persisting traction and/or renewed
proliferation of cells at the VRI, which may lead to later
recurrent traction. ILM peeling can avoid this and indeed the
rate of late reopening of macular holes is anecdotally higher
without ILM peeling. However, mechanical manipulation of
the VRI, including ILM peeling can cause iatrogenic damage
to the macula including inadvertent impact site and tear
formation although these are rare. Superficial retinal
haemorrhages are not uncommon after ILM peeling
although they do not seem to be visually significant in most
cases.97 As mentioned previously, ILM peeling can be
associated with a number of other consequences, the effects
of which are uncertain, including the appearance of a
disassociated optic nerve fibre layer.127,128
In case series and reviews of patients undergoing
20-gauge conventional PPV, the reported incidence of
iatrogenic peripheral retinal breaks has been variable,
ranging from 6 to 36%.97,103,110,129–131 In eyes requiring
surgical PVD induction (most cases of IMH and VMT),
the risk of peripheral iatrogenic retinal breaks is
approximately three times higher than in eyes with pre-
existing complete PVD.131,132 The reported rates of
peripheral retinal break formation appear to be lower
with narrow-gauge TSV using cannulated sclerostomy
systems with breaks reported in 11–16% of procedures,
and only 3 6% related to sclerostomies.110,130,132–134
Retinal detachment has been reported in B2 6% of
patients undergoing PPV for IMH.97,129,132,133,136–139
Symptomatic peripheral field defects are an
uncommon finding (o1% of procedures) following PPV
for IMH.140,141 These are usually temporal and possibly
related to vitreous separation or the consequences of
fluid/air-exchange during surgery.
Cataracts are very common following vitrectomy,
especially in the460 year-old age group and when long-
acting gases are used. Progression of existing cataracts in
patient undergoing PPV for IMH has been reported in
34% of patients at 12 months following the
procedure.142,143 Combined phacovitrectomy has been
widely adopted to avoid the need for subsequent cataract
surgery. However, potential adverse effects of the
procedure can be a higher incidence of posterior synechei
formation and intraocular lens-related complications and
a small (B0.5 dioptre) myopic shift in refraction.
Conversely, sequential surgery has been associated with
a higher rate of posterior capsule rupture and other
operative difficulties during the subsequent cataract
surgery, associated with the lens–iris diaphragm
syndrome after vitrectomy.144–146
Minor vitreous haemorrhage (with spontaneous
resolution) has been reported for B5% of eyes
undergoing 23-gauge TSV.138 Hypotony related to
wound leakage is a concern with sutureless PPV,
occurring in a reported 3–16% of eyes.136,147 In the
majority of cases, this resolves spontaneously and its
incidence is reducing as sclerostomy entry systems
improve. However, there is an increased risk of
complications such as hypotony-related retinopathy,
choroidal effusions, and choroidal haemorrhage in severe
cases.101,147
Endophthalmitis is very rare, occurring in B0.02–
0.05% of cases. Initially, narrow-gauge vitrectomy was
thought to be associated with a higher incidence of
endophthalmitis than 20-gauge PPV; however, this has
not proven to be true.148,149
Ocriplasmin
The principal aim of pharmacological vitreolysis is to
cleave the VRI where a persistent VMA is present,
resulting in complete PVD. First, plasmin, which acts by
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breaking down the fibronectin and laminin within the
VRI, was found to degrade the attachment of the collagen
fibrils to the ILM following intravitreal injection in
human cadaver eyes.150,151 Ocriplasmin, which is a
recombinant truncated form of human plasmin,
demonstrates a substantially longer half-life in the blood
than plasmin but retains the biological actions of the
intact enzyme.152
The effects of ocriplasmin were firstly studied on human
donor eyes.152 Intravitreal administration achieved a
complete VRI separation at the two highest doses
administered, leaving an almost bare ILM with few
remaining collagen fibrils. In animal studies, intravitreal
ocriplasmin demonstrated a dose-dependent degree of
PVD induction.152–154 All PVDs occurred within
60 minutes of ocriplasmin administration, and histological
assessments indicated that retinal integrity was
maintained. In animals with complete PVD, the surface of
the ILM was smooth and collagen fibrils were absent.
Ocriplasmin (Jetrea) has been licensed in Europe and
the USA for treatment in patients with symptomatic
VMA/VMT including when associated with MH less
than 400 microns. Ocriplasmin has also recently been
approved for funding by the UK’s National Institute for
Health and Care Excellence (NICE) in patients without
ERM, but who have either VMT with severe symptoms or
VMT with MH with or without severe symptoms.
Clinical efficacy
Ocriplasmin was initially evaluated before vitrectomy to
assess its effectiveness in the achievement of complete
PVD. A preliminary clinical study assessed intravitreal
ocriplasmin at doses of 25, 50, 75 and 125mg
administered either 1–2 h, 24 h, or 7 days before planned
PPV for VMT.155 Increasing duration of exposure to
ocriplasmin was associated with a progressive increase
in the incidence of complete PVD achievement.
In initial studies, a dose–response relationship for
complete PVD was also observed. A subsequent Phase II,
randomised, double-blind, placebo-controlled trial in 125
patients with VMT or IMH scheduled for PPV evaluated
intravitreal ocriplasmin at doses of 25, 75, and 125 mg
administered 7 days before surgery.156 Complete PVD
demonstrated at the time of vitrectomy was similar for
placebo and ocriplasmin 25mg (10 vs 14%), but dose-
dependently higher with the 75mg, and 125 mg doses (18
and 31%, respectively). Resolution of VRI abnormality
precluding the need for vitrectomy was observed in 31%
of patients randomised to ocriplasmin 125 mg at 35 days
after administration, and in 28% of patients at 180 days.
This dose of ocriplasmin was therefore selected for
further evaluation. A separate Phase II study evaluated
ocriplasmin in patients with VMA, with or without
IMH.157 At 28 days after administration, resolution of
VMA was achieved in 44% of patients receiving 125 mg
ocriplasmin vs 8% of patients in the control group.
Two separate Phase III randomised, double-blind,
placebo-controlled clinical trials with similar designs
were conducted to assess the effects of a single
intravitreal injection of ocriplasmin 125 mg in patients
with VMT and/or IMH (holeso400 mm minimum linear
diameter and with VMT to the edges of the hole).158
At 7 days after treatment, the percentage of eyes with
resolution of VMA was significantly greater with
ocriplasmin than with placebo (OR: 5.20; 95% CI:
2.53–12.07; Po0.001). After 28 days this superiority of
ocriplasmin relative to placebo was maintained (26.5 vs
10.1%; OR: 3.28; 95% CI: 1.93 5.84; Po0.001). Complete
PVD was achieved in 13.4% of eyes receiving ocriplasmin
and 3.7% of patients receiving placebo (Po0.001).
Closure of IMH was observed in 41% of eyes in the
ocriplasmin group and 11% of eyes in the placebo group
(Po0.001). Smaller macular holes closed more frequently
than larger ones, with a 58.3% closure rate in holes
o250mm and 24.6% closure in holes 250–400 mm in size.
VA improved by at least three Snellen lines in a greater
proportion of eyes in the ocriplasmin group relative to
placebo. Resolution of VMA was significant for
ocriplasmin vs placebo in both men (18.7 vs 5.5%; OR:
3.38; 95% CI: 1.25 15.75; P¼ 0.01) and women (30.3 vs
13.0%; OR: 2.94; 95% CI: 1.60 5.76; Po0.001).158 There
was higher success rate of VMT release in patients with
widths of VMA o1500 mm than those Z1500 mm, and a
lower success rate in those with ERM than those without
associated ERM (8.7 vs 37.4%). A subsequent multivariate
analysis of data from these Phase III studies identified
the following baseline characteristics as indicative of
treatment success with ocriplasmin: the presence of a
full-thickness IMH, VMA diameter r1500 mm, phakic
lens, absence of ERM, and patient age o65 years.159
Quality of life was measured using the National Eye
Institute Visual Functioning Questionnaire-25 (VFQ-25).158
Mean improvements from baseline to study endpoint were
significant for ocriplasmin vs placebo for the items general
vision (P¼ 0.006), distance vision (P¼ 0.03), dependency
(P¼ 0.009), driving (P¼ 0.03), and the VFQ-25 composite
score (P¼ 0.007).160 In the placebo group, mean scores for
general health, dependency, and driving all deteriorated
from baseline to the end of the study.
Safety The safety profile of ocriplasmin has been
evaluated in a number of clinical studies. The most
commonly reported adverse events in the two Phase III
trials included vitreous floaters (ocriplasmin, 16.8% vs
placebo, 7.5%; P¼ 0.002), conjunctival haemorrhage
(14.6 vs 12.8%), photopsia (11.8 vs 2.7%; Po0.001), and
injection-related eye pain (13.5 vs 5.9%; P¼ 0.005)
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(Table 2).158 Secondary macular hole development
occurred in 5.2% of patients randomised to ocriplasmin
and 8.6% of patients randomised to placebo. Retinal
detachment was uncommon, reported for 0.4 and 1.6% of
patients receiving ocriplasmin and placebo, respectively.
Reduced VA occurred in less than 1% of patients in either
treatment group, although clinical experience has shown
that transient worsening of vision with increasing traction
before vitreoretinal separation is achieved can occur and
patients should be warned of this possibility.161
Animal studies have indicated an effect of ocriplasmin
on fibronectin and laminin at the outer retina.162
However, to date only a single case has been reported,
which was associated with transient vision loss.161
Importantly in patients receiving ocriplasmin, there have
been no detrimental effects on the subsequent outcome of
vitrectomy surgery.
Medical specialties and referral pathways
Patients will present to both medical and surgical retina
specialists, as the symptoms of VMT and MH are not
specific to these disorders (eg, wet AMD is associated
with similar symptoms). However, early referral of
patients with VMT and MH will allow assessment and
optimal management. In particular, patients with MH are
best seen when VMT is present and the hole is small, as
the results of intervention are favourable. Such cases
with an MLD of less than 400 microns are amenable to
treatment with ocriplasmin. A fast-track referral system
such as that in place for patients with wet AMD should
be available. However, ocriplasmin is not effective in all
cases treated. Importantly the effect of ocriplasmin on
vitreous separation is seen within the first month.
Therefore, in order to avoid surgical delay, patients could
be listed for vitrectomy (certainly for IMH) at the same
time as ocriplasmin is administered. This means that if
results with ocriplasmin are not optimal waiting time is
not further prolonged.
Current guidelines
There are currently no published consensus guidelines
for the management of VMT. However, some general
recommendations can be made. Patients should be
observed for 2–3 months to see if spontaneous resolution
occurs, although this is dependent on symptom severity
and impact on the individual patient’s quality of life. If
there is no resolution, treatment with ocriplasmin should
be considered, taking into account factors such as the
width of the VMA, presence of ERM, the status of the
affected eye’s lens, and patient age.158,159 Surgery, as
opposed to ocriplasmin is recommended if significant
ERM is present.
IMH should be treated early, especially if symptoms
are significant and affecting quality of life. Ocriplasmin
can be considered if hole diameter is o400 mm and VMT
is also present. Patient-dependent factors such as
systemic morbidity and ability to undergo surgery must
also be taken into account. However, if the IMH is not
successfully closed after a maximum of 1 month after
ocriplasmin administration, vitrectomy should be
performed. If an IMH is 4400 mm diameter and VMT is
absent, vitrectomy is routinely recommended as the
primary procedure in all cases. Under these
circumstances, ILM peeling and probably face-down
posturing improves results. Simultaneous cataract
surgery can be performed, especially if the patient is
aged more than 60 years. The minimum effective amount
of dye should be used for staining.
Future research
A number of unanswered questions remain regarding
the pathophysiology of, and current interventions for,
VMT and IMH. A greater understanding of the role of
Table 2 Most frequently reported treatment-emergent ocular
adverse events in two randomised, double-blind placebo-
controlled studies comparing intravitreal ocriplasmin with
placebo (adapted from Stalmans et al158)
Adverse event
Placebo
(n¼ 187)
No. of
events (%)
Ocriplasmin
(n¼ 465)
No. of
events (%) P-valuea
Any ocular adverse event
Vitreous floatersb 14 (7.5) 78 (16.8) 0.002
Photopsiab 5 (2.7) 55 (11.8) o0.001
Conjunctival
haemorrhage
24 (12.8) 68 (14.6) 0.53
Injection-related eye
painb
11 (5.9) 63 (13.5) 0.005
Blurred visionb 6 (3.2) 40 (8.6) 0.01
Visual impairmentb 3 (1.6) 25 (5.4) 0.02
Increased intraocular
pressure
10 (5.3) 18 (3.9) 0.50
Retinal tear 5 (2.7) 6 (1.3) 0.25
Cataract 17 (9.1) 26 (5.6) 0.13
Any ocular serious adverse eventsc
Macular hole 16 (8.6) 24 (5.2) 0.15
Retinal detachment 3 (1.6) 2 (0.4) 0.16
Reduced visual acuity 1 (0.5) 3 (0.6) 0.94
a Calculated by the Cochran–Mantel–Haenszel test, stratified according to
study.
b Based on subjective reports by study participants.
c Identified as such by the investigator and defined as one of the
following: an event resulting in persistent or clinically significant
disability, incapacity, or both; an event requiring in-patient hospitalisation
or prolongation of an existing hospital stay; or an event that was
considered to be medically important.
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VMT in the pathophysiology of wet AMD and DMO
could help to advance treatments of these disorders. In
addition, further and more precise determination of the
IMH features that are associated with the requirement for
face-down posturing and/or ILM peeling for successful
PPV is needed. The role of surgery in symptomatic LMH
also needs clarifying.
Defining patient groups in which response rates to
ocriplasmin are most favourable is a key priority as well
as optimising the timing of intervention in the course of
disease. The potential benefits of ocriplasmin in inducing
vitreous separation with a clean ILM surface and the
possible benefit of vitreous separation early in the disease
course of number of conditions including diabetic
retinopathy could also be investigated.
Summary
PVD is a common phenomenon in the aging eye.
However, this may be complicated by VMT (with or
without ERM) and/or IMH. Technologies such as OCT
allow more accurate visualisation and measurement of
the macular anatomy, facilitating treatment decision-
making. PPV remains the primary treatment option for
many patients with VMT or IMH. However, ocriplasmin
may allow induction of PVD in a non-invasive manner in
some cases. Further research is needed with respect to
greater understanding of the pathophysiology underlying
the development of VMT/IMH, together with the
relationships between these disorders, AMD and DMO.
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Appendix
Appendix Ocriplasmin PI—UK and Ireland
JETREAs. 0.5 mg/0.2 ml concentrate for solution for
injection (ocriplasmin) Prescribing Information
(Refer to full Summary of Product Characteristics
(SmPC) before prescribing)
Presentation: Type I glass vial containing 0.2 ml
concentrate for solution for injection. After dilution
with 0.2 ml sodium chloride 0.9% solution for injection,
0.1 ml of the diluted solution contains 0.125 mg
ocriplasmin. Indication(s): Treatment of vitreomacular
traction (VMT) in adults, including when associated
with macular hole of diameter less than or equal to
400 microns. Posology and method of administration:
Adults, including the elderly: Intravitreal injection of
0.125 mg (0.l ml of the diluted solution) to the affected
eye once only as a single dose. Children and
adolescents: Not recommended. Hepatic and renal
impairment: No dosage adjustment necessary.
Contra-indications: Hypersensitivity to ocriplasmin or
any of the excipients. Active or suspected ocular or
periocular infections. Warnings and precautions:
Proper aseptic injection techniques must always be
used and patients should be monitored for any side
effects such as intraocular inflammation/infection and
elevation in IOP. Patients should be instructed to report
symptoms of intraocular inflammation/infection or
any other visual/ocular symptoms without delay.
Concurrent administration to both eyes or repeated
administration in the same eye is not recommended.
Clinical data is not available on concomitant use with
VEGF-inhibitors. Treatment is not recommended in
patients with large diameter macular holes, high
myopia, aphakia, history of rhegmatogenous retinal
detachment, lens zonule instability, recent ocular
surgery or intraocular injection (including laser
therapy), proliferative diabetic retinopathy, ischaemic
retinopathies, retinal vein occlusions, exudative
age-related macular degeneration (AMD) and vitreous
haemorrhage. There is potential for lens subluxation or
phacodonesis. Exercise caution if treating patients
with non-proliferative diabetic retinopathy, history of
uveitis or significant eye trauma. Ocriplasmin efficacy
is reduced in patients with an epiretinal membrane or
a diameter of VMA 41500 microns. Due to potential
increase in tractional forces, there is a risk of
occurrence of new or enlarged macular holes. There is
a risk of significant but transient loss of visual
acuity during the first week after the injection.
Interactions: Formal studies have not been performed.
Systemic interactions are not anticipated.
Administration in close temporal association, in the
same eye as other medicinal products may affect the
activity of both products and is not recommended.
Pregnancy and lactation: Do not use unless clearly
necessary. Fertility: No fertility data are available.
Effects on ability to drive and use machines: If visual
disturbances occur, wait until vision clears before
driving or operating machinery. Undesirable effects:
Very common: vitreous floaters, eye pain, conjunctival
haemorrhage. Common: visual acuity reduced, visual
impairment, vision blurred, intraocular pressure
increased, metamorphopsia, conjunctival oedema,
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eyelid oedema, photopsia, conjunctival hyperaemia,
ocular hyperaemia, retinogram abnormal, eye
irritation, dry eye, foreign body sensation in eyes,
eye pruritus, ocular discomfort, photophobia,
chromatopsia. Serious: retinal haemorrhage, vitreous
haemorrhage, retinal tear, retinal detachment, macular
hole, macular degeneration, retinal degeneration,
macular oedema, retinal oedema, retinal pigment
epitheliopathy, vitreous adhesions, vitritis, anterior
chamber cell, anterior chamber flare, iritis, vitreous
detachment, transient blindness, lens subluxation,
scotoma, visual field defect, hyphaema, pupils
unequal, corneal abrasion, anterior chamber
inflammation. In addition: diplopia, miosis, eye
inflammation, conjunctival irritation. Prescribers
should consult the SmPC in relation to the side effects.
Overdose: Clinical data are limited. If an overdose
occurs, close monitoring is recommended.
Incompatibilities: Must not be mixed with other
medicinal products except for the specified
diluent. Special Precautions for Storage: Store frozen
at  20 1C±5 1C. Legal Category: POM. Package
Quantities and Basic NHS Costs: 1 0.2 ml vial
d2,500. Ireland Price: h3,099. MA Number(s): EU/1/
13/819/001. Further information available from the
MA holder: ThromboGenics NV, Gaston Geenslaan
1, B-3001 Leuven, Belgium. Distributer: Alcon
Laboratories (UK) Limited, Frimley Business Park,
Frimley, Camberley, Surrey, GU16 7SR. Date of
preparation: June 2013 (V2).
Adverse events should be reported. Reporting forms
and information can be found at www.mhra.gov.uk/
yellowcard. Adverse events should also be reported
to Alcon Medical Information. Tel: 0871 376 1402.
Email: gb.adr@alcon.com
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